{
  "NCT06074588": {
    "verdict": "EXCLUDED",
    "mode": "two_stage",
    "criteria": [
      {
        "text": "Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations.",
        "type": "inclusion",
        "verdict": "NOT_MET",
        "reasoning": "The medical analysis concludes that the patient does not satisfy the criterion requiring documented advanced or metastatic non-squamous NSCLC with specific mutations, despite the histopathologic confirmation of malignancy.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires the patient to have histologically or cytologically documented advanced (Stage III) non-small cell lung cancer (NSCLC) that is not eligible for resection or curative radiation, or metastatic non-squamous NSCLC with specific mutations.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note states that \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy, showing extensive lymphovascular invasion, focal necrosis, and signet-ring cells.\" This indicates the presence of malignancy.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    Answer: NO\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    Confidence: LOW"
      },
      {
        "text": "Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.",
        "type": "inclusion",
        "verdict": "NOT_MET",
        "reasoning": "The clinical note describes current radiological findings such as lung nodules and masses, but it does not provide documentation of disease progression over time or mention the use of RECIST 1.1 criteria, which are specific requirements for this inclusion criterion.",
        "evidence_sentences": [
          0
        ],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). This means the note should describe how the patient's lung nodules or masses have changed in size or number, or if new lesions have appeared, compared to previous imaging, and that these changes were assessed by a radiologist.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note mentions \"Axial CT images of the chest demonstrate nodular and branching opacities in the right upper lobe, consistent with a tree-in-bud pattern. A large, well-circumscribed mass is present in the left lower lobe. Additionally, there is evidence of interstitial changes in the right lung, including honeycombing and pleural thickening, particularly in the right lower lobe, along with a small right-sided pleural effusion.\" This describes the patient's lung findings on CT.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    Answer: NO\n4.  **How confident are you?**\n    Confidence: LOW"
      },
      {
        "text": "Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The clinical note lacks any information regarding the patient's prior treatment history, including the specific use of EGFR TKIs or platinum-based therapies required for this inclusion criterion. Since the medical analysis confirms this information is not provided, the eligibility status cannot be determined.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    This criterion requires that patients with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI.\n\n2.  What does the patient note state about this? Cite specific sentences by index.\n    The patient note does not mention any prior treatment history, including EGFR TKIs or platinum-based therapies. The note states: \"Information not provided includes cancer stage, performance status, and prior treatment history.\"\n\n3.  Does the patient have or satisfy the condition described in this criterion?\n    Answer: NO\n4.  How confident are you? HIGH / MEDIUM / LOW\n    Answer: LOW"
      },
      {
        "text": "Measurable disease per RECIST 1.1 as assessed by the local site investigator.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The medical analysis states that while the patient has imaging findings like a mass and opacities, the note lacks the specific measurements or explicit investigator assessment required to determine if the disease is 'measurable' according to RECIST 1.1 criteria.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires the patient to have a measurable disease per RECIST 1.1 as assessed by the local site investigator.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note does not explicitly state that the patient has a measurable disease per RECIST 1.1. The note mentions imaging findings, including a large mass in the left lower lobe and nodular/branching opacities in the right upper lobe, along with interstitial changes and a pleural effusion. However, it does not provide information on the size of these lesions or whether they meet the criteria for measurable disease according to RECIST 1.1.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    INSUFFICIENT DATA\n\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    LOW"
      },
      {
        "text": "Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The clinical note confirms that histopathologic analysis of tissue from the lung and lymph nodes was performed, which indicates that tumor tissue samples are available for the patient.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires the patient to have a sample of archival tumor tissue or a newly obtained core, incisional, or excisional biopsy of a tumor lesion that has not been previously irradiated.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note states: \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy, showing extensive lymphovascular invasion, focal necrosis, and signet-ring cells.\"\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    Answer: YES\n\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    Answer: HIGH"
      },
      {
        "text": "Participants who have AEs due to previous anticancer therapies must have recovered to Grade \u22641 or baseline.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The patient's note contains no information about prior anticancer therapies or any associated adverse events, so it cannot be determined if they have recovered to the required grade.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires that patients who have experienced adverse events (AEs) due to previous anticancer therapies must have recovered to a Grade \u22641 or their baseline condition.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note does not mention any prior anticancer therapies or any AEs related to them.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    NO\n\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    LOW"
      },
      {
        "text": "Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The clinical note contains no information regarding the patient's Hepatitis B surface antigen status, HBV antiviral therapy history, or HBV viral load, which are required to determine eligibility for this inclusion criterion.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    This criterion requires that a patient must be Hepatitis B surface antigen (HBsAg) positive, have received HBV antiviral therapy for at least 4 weeks, and have an undetectable HBV viral load prior to randomization.\n\n2.  What does the patient note state about this? Cite specific sentences by index.\n    The patient note does not mention the patient's Hepatitis B status, antiviral therapy history, or viral load.\n\n3.  Does the patient have or satisfy the condition described in this criterion?\n    NO\n\n4.  How confident are you?\n    LOW"
      },
      {
        "text": "Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The clinical note does not provide information regarding the patient's HIV status or whether they are receiving antiretroviral therapy, preventing a determination of eligibility for this inclusion criterion.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires that HIV-infected participants must have well-controlled HIV on antiretroviral therapy.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note does not mention the patient's HIV status or whether it is well-controlled.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    INSUFFICIENT DATA\n\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    LOW"
      },
      {
        "text": "Have an ECOG performance status of 0 or 1 within 3 days before randomization.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The patient note does not mention the patient's ECOG performance status, so it cannot be determined if the patient meets this inclusion criterion.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires the patient to have an ECOG performance status of 0 or 1 within 3 days before randomization.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note does not mention the patient's ECOG performance status or any information about their status within 3 days before randomization.\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    NO\n\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    LOW"
      },
      {
        "text": "Has predominantly squamous cell histology NSCLC.",
        "type": "exclusion",
        "verdict": "NOT_MET",
        "reasoning": "The medical analysis indicates that the patient's histopathology showed signet-ring cells, which are associated with adenocarcinoma rather than squamous cell histology. Since the patient does not have the excluded condition, they are eligible.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  **What does this criterion specifically require?**\n    This criterion requires the patient to have predominantly squamous cell histology NSCLC.\n\n2.  **What does the patient note state about this? Cite specific sentences by index.**\n    The patient note states: \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy, showing extensive lymphovascular invasion, focal necrosis, and signet-ring cells.\"\n\n3.  **Does the patient have or satisfy the condition described in this criterion?**\n    Answer: NO\n4.  **How confident are you? HIGH / MEDIUM / LOW**\n    Confidence: LOW"
      }
    ]
  }
}